WARNING LETTER

VIA EMAIL TO info@goldensunrisepharmaceutical.com

Golden Sunrise Pharmaceutical
P.O. Box 510
Porterville, California 93258

Re: Unsubstantiated Claims for Coronavirus Prevention or Treatment

To Whom It May Concern,

This is to advise you that FTC staff has reviewed your website at https://goldensunrisepharmaceutical.com/ on April 25, 2020. We have determined that you are unlawfully advertising that certain products treat or prevent Coronavirus Disease 2019 (COVID-19).

Some examples of Coronavirus treatment or prevention claims on your website include:


- In marketing materials titled “Emergency D-Virus Plan of Care,” claiming, “ImunStem and Aktiffvate, along with their AnterFeerons product, as uniquely qualified to treat and modify the course of the Coronavirus epidemic in CHINA and other countries. Patients with late stages of COVID-19, Hepatitis C, and AIDS / HIV have responded with greatly improved quality-of-life and extending their lives when treated with ImunStem and Aktiffvate.”

- In connection with marketing a treatment for COVID-19, claiming, “ImunStem and Aktiffvate herbs are the basis of the whole cellular therapy developed by Golden Sunrise Nutraceautical. They have proven themselves to the United States Food & Drug Administration (FDA). ImunStem, an herbal product, was the first dietary supplement in the United States to be approved as a prescription medicine and also for the indication to
treat *Serious or Life-threatening* conditions.”

- In marketing materials titled “Emergency D-Virus Plan of Care,” under a section titled “Summary,” claiming, “All patients have become completely asymptomatic by day number seven (#7) to day number nine (#9) of treatment with the **EMERGENCY D-Virus Plan of Care**. Once people are afebrile for three (3) days and with improved cough, current policy allows discontinuation of self-quarantine measures. Up until now, because there has been no effective treatment, the effort of controlling the **COVID-19** virus pandemic has necessitated a preventative approach, utilizing social isolation measures and testing. Success with these measures come at great cost both socially and economically. Now with the **EMERGENCY D-Virus Plan of Care** showing effective treatment for the **COVID-19** virus, the focus can change, at it should, from prevention to treatment. Social isolation and **COVID-19** testing can be significantly adjusted with treatment taking the primary approach of controlling the **COVID-19** virus. Prompt administration of this treatment will significantly diminish the occurrence of serious cases and need for hospitalization.”

- In marketing materials titled “Emergency D-Virus Plan of Care,” under a section titled “Results of Patients After Treatment,” claiming, “The group of patients **COVID-19** virus found that **EMERGENCY D-Virus Plan of Care** improved the immune system and alertness immediately. Physicians have observed that using **EMERGENCY D-Virus Plan of Care** provokes a significant response, i.e., a reduction in symptoms in patients with the **COVID-19** virus….”

It is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For **COVID-19**, no such study is currently known to exist for the product identified above. Thus, any Coronavirus-related prevention or treatment claims regarding such product are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims.

You are also advised to review all other claims for your products and immediately cease making claims that are not supported by competent and reliable scientific evidence.

Within 48 hours, please send a message to James E. Elliott via electronic mail at jelliott@ftc.gov describing the specific actions you have taken to address the FTC’s concerns. If you have any questions regarding compliance with the FTC Act, please contact Zachary A. Keller at zkeller@ftc.gov.

Very truly yours,

**DAMA BROWN**

Dama J. Brown
Regional Director
Southwest Region